<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40886309</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>31</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation: The ALONE-AF Randomized Clinical Trial.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e2514679</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2025.14679</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="UNASSIGNED">Data from randomized clinical trials on a long-term anticoagulation strategy for patients after catheter-based ablation for atrial fibrillation (AF) are lacking.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To evaluate whether discontinuing oral anticoagulant therapy provides superior clinical outcomes compared with continuing oral anticoagulant therapy in patients without documented atrial arrhythmia recurrence after catheter ablation for AF.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="UNASSIGNED">A randomized clinical trial including 840 adult patients (aged 19-80 years) who were enrolled and randomized from July 28, 2020, to March 9, 2023, at 18 hospitals in South Korea. Enrolled patients had at least 1 non-sex-related stroke risk factor (determined using the CHA2DS2-VASc score [range, 0-9]) and no documented recurrence of atrial arrhythmia for at least 1 year after catheter ablation for AF. The CHA2DS2-VASc score is used as an assessment of stroke risk among patients with AF (calculated using point values for congestive heart failure, hypertension, &#x2265;75 years of age, diabetes, stroke or transient ischemic attack, vascular disease, between 65 and 74 years of age, and sex category). The date of final follow-up was June 4, 2025.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="UNASSIGNED">The patients were randomly assigned in a 1:1 ratio to discontinue oral anticoagulant therapy (n&#x2009;=&#x2009;417) or continue oral anticoagulant therapy (with direct oral anticoagulants; n&#x2009;=&#x2009;423).</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="UNASSIGNED">The primary outcome was the first occurrence of a composite of stroke, systemic embolism, and major bleeding at 2 years. Individual components of the primary outcome (such as ischemic stroke and major bleeding) were assessed as secondary outcomes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Of the 840 adults randomized, the mean age was 64 (SD, 8) years, 24.9% were women, the mean CHA2DS2-VASc score was 2.1 (SD, 1.0), and 67.6% had paroxysmal AF. At 2 years, the primary outcome occurred in 1 patient (0.3%) in the discontinue oral anticoagulant therapy group vs 8 patients (2.2%) in the continue oral anticoagulant therapy group (absolute difference, -1.9 percentage points [95% CI, -3.5 to -0.3]; P&#x2009;=&#x2009;.02). The 2-year cumulative incidence of ischemic stroke was 0.3% in the discontinue oral anticoagulant therapy group vs 0.8% in the continue oral anticoagulant therapy group (absolute difference, -0.5 percentage points [95% CI, -1.6 to 0.6]). Major bleeding occurred in 0 patients in the discontinue oral anticoagulant therapy group vs 5 patients (1.4%) in the continue oral anticoagulant therapy group (absolute difference, -1.4 percentage points [95% CI, -2.6 to -0.2]).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="UNASSIGNED">Among patients without documented atrial arrhythmia recurrence after catheter ablation for AF, discontinuing oral anticoagulant therapy resulted in a lower risk for the composite outcome of stroke, systemic embolism, and major bleeding vs continuing direct oral anticoagulant therapy.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="UNASSIGNED">ClinicalTrials.gov Identifier: NCT04432220.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Daehoon</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shim</LastName><ForeName>Jaemin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Korea University Hospital, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Eue-Keun</ForeName><Initials>EK</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oh</LastName><ForeName>Il-Young</ForeName><Initials>IY</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Seoul National University Bundang Hospital, Seongnam, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Heart Institute, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Young Soo</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Daegu Catholic University Hospital, Daegu, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Junbeom</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Ewha Womans University Hospital, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ko</LastName><ForeName>Jum-Suk</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Wonkwang University School of Medicine and Hospital, Iksan, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Kyoung-Min</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Heart Vascular and Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sung</LastName><ForeName>Jung-Hoon</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Division of Cardiology, CHA Bundang Medical Center, CHA University, Seongnam, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Hyung Wook</ForeName><Initials>HW</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Internal Medicine, Chonnam National University Hospital, Gwangju, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Hyung-Seob</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Keimyung University Hospital, Daegu, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jong-Youn</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Gangnam Severance Hospital, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Ki-Woon</ForeName><Initials>KW</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Chung-Ang University Hospital, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Dongmin</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Dankook University College of Medicine, Cheonan, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jin-Kyu</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Hanyang University Seoul Hospital, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Dae-Hyeok</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Inha University College of Medicine and Inha University Hospital, Incheon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jin-Bae</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Kyung Hee University Medical Center, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Hee Tae</ForeName><Initials>HT</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Tae-Hoon</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uhm</LastName><ForeName>Jae-Sun</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pak</LastName><ForeName>Hui-Nam</ForeName><Initials>HN</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joung</LastName><ForeName>Boyoung</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>ALONE-AF Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04432220</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.1001/jama.2025.14669</RefSource></CommentsCorrections></CommentsCorrectionsList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Choi reported receiving grants or speaking fees from Abbott, Bayer, BMS/Pfizer, Biosense Webster, Chong Kun Dang, Daewoong Pharmaceutical Co, Daiichi-Sankyo, DeepQure, Dreamtech Co Ltd, Jeil Pharmaceutical Co Ltd, Medtronic, Samjinpharm, Samsung Electronics Co Ltd, Seers Technology, Skylabs, and Yuhan Corporation. Dr Joung reported receiving speaking fees from Bayer, BMS/Pfizer, Medtronic, and Daiichi-Sankyo and receiving research funding from Samjin, Yuhan, Medtronic, Boston Scientific, and Abbott Korea. No other disclosures were reported.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Joung</LastName><ForeName>Boyoung</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Uhm</LastName><ForeName>Jae-Sun</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>Tae-Hoon</ForeName><Initials>TH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yu</LastName><ForeName>Hee Tae</ForeName><Initials>HT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>Daehoon</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Park</LastName><ForeName>Hanjin</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shim</LastName><ForeName>Jaemin</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Choi</LastName><ForeName>Eue-Keun</ForeName><Initials>EK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>So-Ryoung</ForeName><Initials>SR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oh</LastName><ForeName>Il-Young</ForeName><Initials>IY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>Jun</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Choi</LastName><ForeName>Kee-Joon</ForeName><Initials>KJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nam</LastName><ForeName>Gi-Byoung</ForeName><Initials>GB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cho</LastName><ForeName>Min Soo</ForeName><Initials>MS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Young Soo</ForeName><Initials>YS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Park</LastName><ForeName>Junbeom</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ko</LastName><ForeName>Jum-Suk</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Park</LastName><ForeName>Kyoung-Min</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sung</LastName><ForeName>Jung-Hoon</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Park</LastName><ForeName>Hyung Wook</ForeName><Initials>HW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Park</LastName><ForeName>Hyoung-Seob</ForeName><Initials>HS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hwang</LastName><ForeName>JongMin</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chung</LastName><ForeName>Tae-Wan</ForeName><Initials>TW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>Jong-Youn</ForeName><Initials>JY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>In-Soo</ForeName><Initials>IS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kang</LastName><ForeName>Ki-Woon</ForeName><Initials>KW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>Dongmin</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Park</LastName><ForeName>Jin-Kyu</ForeName><Initials>JK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>Dae-Hyeok</ForeName><Initials>DH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baek</LastName><ForeName>Yong-Soo</ForeName><Initials>YS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>Jin-Bae</ForeName><Initials>JB</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2026</Year><Month>3</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>2</Day><Hour>4</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>2</Day><Hour>4</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>31</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40886309</ArticleId><ArticleId IdType="pmc">PMC12400166</ArticleId><ArticleId IdType="doi">10.1001/jama.2025.14679</ArticleId><ArticleId IdType="pii">2838294</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation. Circulation. 2024;149(1):e1-e156. doi: 10.1161/CIR.0000000000001193</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000001193</ArticleId><ArticleId IdType="pmc">PMC11095842</ArticleId><ArticleId IdType="pubmed">38033089</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3314-3414. doi: 10.1093/eurheartj/ehae176</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehae176</ArticleId><ArticleId IdType="pubmed">39210723</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D, Yang PS, Jang E, et al. Increasing trends in hospital care burden of atrial fibrillation in Korea, 2006 through 2015. Heart. 2018;104(24):2010-2017. doi: 10.1136/heartjnl-2017-312930</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2017-312930</ArticleId><ArticleId IdType="pubmed">29666179</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D, Yang PS, Jang E, et al. 10-Year nationwide trends of the incidence, prevalence, and adverse outcomes of non-valvular atrial fibrillation nationwide health insurance data covering the entire Korean population. Am Heart J. 2018;202:20-26. doi: 10.1016/j.ahj.2018.04.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2018.04.017</ArticleId><ArticleId IdType="pubmed">29802976</ArticleId></ArticleIdList></Reference><Reference><Citation>Mark DB, Anstrom KJ, Sheng S, et al. Effect of catheter ablation vs medical therapy on quality of life among patients with atrial fibrillation. JAMA. 2019;321(13):1275-1285. doi: 10.1001/jama.2019.0692</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2019.0692</ArticleId><ArticleId IdType="pmc">PMC6450275</ArticleId><ArticleId IdType="pubmed">30874716</ArticleId></ArticleIdList></Reference><Reference><Citation>Packer DL, Mark DB, Robb RA, et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation. JAMA. 2019;321(13):1261-1274. doi: 10.1001/jama.2019.0693</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2019.0693</ArticleId><ArticleId IdType="pmc">PMC6450284</ArticleId><ArticleId IdType="pubmed">30874766</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirchhof P, Camm AJ, Goette A, et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med. 2020;383(14):1305-1316. doi: 10.1056/NEJMoa2019422</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2019422</ArticleId><ArticleId IdType="pubmed">32865375</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzeis S, Gerstenfeld EP, Kalman J, et al. 2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation. EP Europace. 2024;26(4):euae043. doi: 10.1093/europace/euae043</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/euae043</ArticleId><ArticleId IdType="pmc">PMC11000153</ArticleId><ArticleId IdType="pubmed">38587017</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkle RA, Mead RH, Engel G, et al. Discontinuing anticoagulation following successful atrial fibrillation ablation in patients with prior strokes. J Interv Card Electrophysiol. 2013;38(3):147-153. doi: 10.1007/s10840-013-9835-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10840-013-9835-1</ArticleId><ArticleId IdType="pmc">PMC3825152</ArticleId><ArticleId IdType="pubmed">24101149</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaita F, Sardi D, Battaglia A, et al. Incidence of cerebral thromboembolic events during long-term follow-up in patients treated with transcatheter ablation for atrial fibrillation. Europace. 2014;16(7):980-986. doi: 10.1093/europace/eut406</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/eut406</ArticleId><ArticleId IdType="pubmed">24446510</ArticleId></ArticleIdList></Reference><Reference><Citation>Ha AC, Hindricks G, Birnie DH, Verma A. Long-term oral anticoagulation for patients after successful catheter ablation of atrial fibrillation. Curr Opin Cardiol. 2015;30(1):1-7. doi: 10.1097/HCO.0000000000000121</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HCO.0000000000000121</ArticleId><ArticleId IdType="pubmed">25389647</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanaoka K, Nishida T, Iwanaga Y, et al. Oral anticoagulation after atrial fibrillation catheter ablation. Eur Heart J. 2024;45(7):522-534. doi: 10.1093/eurheartj/ehad798</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehad798</ArticleId><ArticleId IdType="pmc">PMC10873714</ArticleId><ArticleId IdType="pubmed">38117227</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D, Shim J, Choi EK, et al. The Anticoagulation One year after Ablation of Atrial Fibrillation in Patients with Atrial Fibrillation (ALONE-AF) trial. Heliyon. 2024;10(16):e36506. doi: 10.1016/j.heliyon.2024.e36506</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2024.e36506</ArticleId><ArticleId IdType="pmc">PMC11379993</ArticleId><ArticleId IdType="pubmed">39247263</ArticleId></ArticleIdList></Reference><Reference><Citation>Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992. doi: 10.1056/NEJMoa1107039</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1107039</ArticleId><ArticleId IdType="pubmed">21870978</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-891. doi: 10.1056/NEJMoa1009638</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1009638</ArticleId><ArticleId IdType="pubmed">21830957</ArticleId></ArticleIdList></Reference><Reference><Citation>ROCKET AF Study Investigators . Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. Am Heart J. 2010;159(3):340-347.e1. doi: 10.1016/j.ahj.2009.11.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2009.11.025</ArticleId><ArticleId IdType="pubmed">20211293</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulman S, Anger&#xe5;s U, Bergqvist D, et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost. 2010;8(1):202-204. doi: 10.1111/j.1538-7836.2009.03678.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2009.03678.x</ArticleId><ArticleId IdType="pubmed">19878532</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaatz S, Ahmad D, Spyropoulos AC, Schulman S. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients. J Thromb Haemost. 2015;13(11):2119-2126. doi: 10.1111/jth.13140</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.13140</ArticleId><ArticleId IdType="pubmed">26764429</ArticleId></ArticleIdList></Reference><Reference><Citation>Karasoy D, Gislason GH, Hansen J, et al. Oral anticoagulation therapy after radiofrequency ablation of atrial fibrillation and the risk of thromboembolism and serious bleeding. Eur Heart J. 2015;36(5):307-14a. doi: 10.1093/eurheartj/ehu421</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehu421</ArticleId><ArticleId IdType="pubmed">25368205</ArticleId></ArticleIdList></Reference><Reference><Citation>Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857-867. doi: 10.7326/0003-4819-146-12-200706190-00007</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-146-12-200706190-00007</ArticleId><ArticleId IdType="pubmed">17577005</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds MR, Gunnarsson CL, Hunter TD, et al. Health outcomes with catheter ablation or antiarrhythmic drug therapy in atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2012;5(2):171-181. doi: 10.1161/CIRCOUTCOMES.111.963108</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCOUTCOMES.111.963108</ArticleId><ArticleId IdType="pubmed">22373904</ArticleId></ArticleIdList></Reference><Reference><Citation>Friberg L, Tabrizi F, Englund A. Catheter ablation for atrial fibrillation is associated with lower incidence of stroke and death. Eur Heart J. 2016;37(31):2478-2487. doi: 10.1093/eurheartj/ehw087</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehw087</ArticleId><ArticleId IdType="pubmed">26984861</ArticleId></ArticleIdList></Reference><Reference><Citation>Asad ZUA, Yousif A, Khan MS, et al. Catheter ablation versus medical therapy for atrial fibrillation. Circ Arrhythm Electrophysiol. 2019;12(9):e007414. doi: 10.1161/CIRCEP.119.007414</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCEP.119.007414</ArticleId><ArticleId IdType="pubmed">31431051</ArticleId></ArticleIdList></Reference><Reference><Citation>Noseworthy PA, Yao X, Deshmukh AJ, et al. Patterns of anticoagulation use and cardioembolic risk after catheter ablation for atrial fibrillation. J Am Heart Assoc. 2015;4(11):e002597. doi: 10.1161/JAHA.115.002597</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.115.002597</ArticleId><ArticleId IdType="pmc">PMC4845220</ArticleId><ArticleId IdType="pubmed">26541393</ArticleId></ArticleIdList></Reference><Reference><Citation>Wazni OM, Saliba WI, Nair DG, et al. Left atrial appendage closure after ablation for atrial fibrillation. N Engl J Med. 2025;392(13):1277-1287. doi: 10.1056/NEJMoa2408308</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2408308</ArticleId><ArticleId IdType="pubmed">39555822</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirchhof P, Toennis T, Goette A, et al. Anticoagulation with edoxaban in patients with atrial high-rate episodes. N Engl J Med. 2023;389(13):1167-1179. doi: 10.1056/NEJMoa2303062</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2303062</ArticleId><ArticleId IdType="pubmed">37622677</ArticleId></ArticleIdList></Reference><Reference><Citation>Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806-817. doi: 10.1056/NEJMoa1007432</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1007432</ArticleId><ArticleId IdType="pubmed">21309657</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma A, Champagne J, Sapp J, et al. Discerning the incidence of symptomatic and asymptomatic episodes of atrial fibrillation before and after catheter ablation (DISCERN AF). JAMA Intern Med. 2013;173(2):149-156. doi: 10.1001/jamainternmed.2013.1561</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2013.1561</ArticleId><ArticleId IdType="pubmed">23266597</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguilar M, Macle L, Deyell MW, et al. Influence of monitoring strategy on assessment of ablation success and postablation atrial fibrillation burden assessment. Circulation. 2022;145(1):21-30. doi: 10.1161/CIRCULATIONAHA.121.056109</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.121.056109</ArticleId><ArticleId IdType="pubmed">34816727</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakajima E, Ha ACT, Qiu F, et al. East Asian immigration and direct oral anticoagulant dosing for atrial fibrillation. Heart Rhythm. Published online May 22, 2025. doi: 10.1016/j.hrthm.2025.05.040</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hrthm.2025.05.040</ArticleId><ArticleId IdType="pubmed">40412595</ArticleId></ArticleIdList></Reference><Reference><Citation>Steffel J, Eikelboom JW. Stroke prevention in AF. Eur Heart J. 2019;40(19):1528-1530. doi: 10.1093/eurheartj/ehy776</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehy776</ArticleId><ArticleId IdType="pubmed">30590518</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>